Spots Global Cancer Trial Database for pancreatic ductal adenocarcinoma (pdac)
Every month we try and update this database with for pancreatic ductal adenocarcinoma (pdac) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | NCT05605522 | Pancreatic Duct... Squamous Cell C... Colorectal Canc... Gastric Cancer Ewing Sarcoma NTSR1 Expressin... Neuroendocrine ... | [225]-FPI-2059 [111In]-FPI-205... | 18 Years - | Fusion Pharmaceuticals Inc. | |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | NCT06026410 | Solid Tumors Wi... Non Small Cell ... Colorectal Canc... Pancreatic Duct... Clear Cell Rena... | KO-2806 Cabozantinib Adagrasib | 18 Years - | Kura Oncology, Inc. | |
| A Single-arm Phase II Study to Evaluate the Safety and Efficacy of Combination Systematic Chemotherapy and Multiple Rounds of Endoscopic Ultrasound-guided Radiofrequency Ablation in Pancreatic Cancer | NCT04990609 | Pancreatic Duct... | Endoscopic Ultr... Neoadjuvant che... | 18 Years - | The University of Texas Health Science Center, Houston | |
| Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma | NCT06069778 | Pancreatic Canc... | BNT321 Dose Lev... BNT321 Dose Lev... mFOLFIRINOX BNT321 RP2D | 18 Years - | BioNTech SE | |
| GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors | NCT04083599 | Malignant Solid... Non Small Cell ... Colorectal Canc... Melanoma Head and Neck S... Pancreatic Duct... | GEN1042 Pembrolizumab Cisplatin Carboplatin 5-FU Gemcitabine Nab paclitaxel Pemetrexed Paclitaxel | 18 Years - | Genmab | |
| KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer | NCT06411691 | Colorectal Canc... Pancreatic Canc... | KRAS Vaccine wi... Balstilimab Botensilimab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer | NCT04799431 | Pancreatic Canc... Colorectal Canc... | Neoantigen Vacc... Retifanlimab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | NCT05379985 | Non-small Cell ... Colorectal Canc... Pancreatic Duct... Advanced Solid ... | RMC-6236 | 18 Years - | Revolution Medicines, Inc. | |
| A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | NCT03549000 | Non-small Cell ... Triple Negative... Pancreatic Duct... Colorectal Canc... Ovarian Cancer Renal Cell Carc... Metastatic Cast... | NZV930 PDR001 NIR178 | 18 Years - | Novartis | |
| Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies | NCT02672917 | Pancreatic Canc... | MVT-5873 modified FOLFIR... gemcitabine + n... | 18 Years - | BioNTech SE | |
| Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC | NCT03032913 | Pancreatic Duct... | Blood samples Portal vein blo... | 18 Years - | University Hospital, Bordeaux | |
| A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | NCT06179160 | Solid Tumors | INCB161734 Cetuximab Retifanlimab | 18 Years - | Incyte Corporation | |
| GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors | NCT04083599 | Malignant Solid... Non Small Cell ... Colorectal Canc... Melanoma Head and Neck S... Pancreatic Duct... | GEN1042 Pembrolizumab Cisplatin Carboplatin 5-FU Gemcitabine Nab paclitaxel Pemetrexed Paclitaxel | 18 Years - | Genmab | |
| A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | NCT04943900 | Advanced Solid ... | BMS-986416 Nivolumab | 18 Years - | Bristol-Myers Squibb | |
| A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | NCT04704154 | Solid Tumors | Regorafenib, (S... Nivolumab (Opdi... | 18 Years - | Bayer | |
| A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | NCT05706129 | Clear Cell Rena... Pancreatic Duct... Colorectal Canc... | [68Ga]Ga-DPI-44... [177Lu]Lu-DPI-4... | 18 Years - | Debiopharm International SA | |
| A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | NCT03811652 | Non Small Cell ... Head and Neck S... Small Cell Lung... Pancreatic Duct... Colorectal Canc... Metastatic Cast... | MEDI7247 | 18 Years - 101 Years | MedImmune LLC | |
| Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC | NCT03032913 | Pancreatic Duct... | Blood samples Portal vein blo... | 18 Years - | University Hospital, Bordeaux | |
| A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma | NCT06261359 | Pancreatic Duct... | CEND-1 Gemcitabine Nab paclitaxel | 18 Years - 80 Years | Qilu Pharmaceutical Co., Ltd. | |
| Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer | NCT03977233 | Pancreatic Duct... Cancer of Pancr... Pancreatic Canc... Pancreas Adenoc... Pancreatic Neop... Pancreatic Canc... Pancreatic Canc... | Oxaliplatin Leucovorin Irinotecan Hydr... 5-FU | 18 Years - 99 Years | UNC Lineberger Comprehensive Cancer Center | |
| A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | NCT05706129 | Clear Cell Rena... Pancreatic Duct... Colorectal Canc... | [68Ga]Ga-DPI-44... [177Lu]Lu-DPI-4... | 18 Years - | Debiopharm International SA | |
| A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | NCT04704154 | Solid Tumors | Regorafenib, (S... Nivolumab (Opdi... | 18 Years - | Bayer | |
| A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma | NCT06261359 | Pancreatic Duct... | CEND-1 Gemcitabine Nab paclitaxel | 18 Years - 80 Years | Qilu Pharmaceutical Co., Ltd. | |
| Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study | NCT02782182 | Pancreatic Duct... | FOLFIRINOX (oxa... | 18 Years - | University of Chicago | |
| Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer | NCT03977233 | Pancreatic Duct... Cancer of Pancr... Pancreatic Canc... Pancreas Adenoc... Pancreatic Neop... Pancreatic Canc... Pancreatic Canc... | Oxaliplatin Leucovorin Irinotecan Hydr... 5-FU | 18 Years - 99 Years | UNC Lineberger Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
